Frontier Bio said that in this IPO, the company hopes to improve the layout of the entire R&D industrial chain, the production and commercialization of new drugs with the help of China capital market, and continuously enhance the company's market position and international competitiveness in the biomedical industry at home and abroad.
A number of technologies have achieved breakthroughs! Cutting-edge organisms dig deep into the clinical value of "Aikening"
Biomedical industry is a strategic emerging industry related to the national economy and people's livelihood, social stability and economic development. country
In recent years, supportive industrial policies and laws and regulations promulgated by economists have created a good external environment for the management and development of frontier organisms in the future. According to the Outline of the National Medium-and Long-term Scientific and Technological Development Plan (2006-2020), the creation of major new drugs and the prevention and treatment of major infectious diseases such as AIDS and viral hepatitis are listed as one of the major national projects of 16. This policy has created a good policy environment for the research and development of new frontier biological drugs.
After listing, Aikening quickly entered professional treatment guidelines and expert knowledge (including China AIDS diagnosis and treatment guidelines (version 20 18), AIDS antiviral treatment strategy expert, and China HIV infection perioperative antiviral treatment expert), and established Aikening's academic status and expert recognition. In addition, Aikening was selected as "Top Ten Medical Science and Technology News in China in 20 18". 2019,6543810.9, the national scientific and technological work conference summarized the major national scientific and technological innovations in 20 18, among which Aikening was recognized by the Ministry of Science and Technology as a major breakthrough in the field of new drug creation, together with the scientific and technological achievements such as the Chang 'e-4 landing on the moon and the opening of the Hong Kong-Zhuhai-Macao Bridge.
It is understood that Aikening has achieved technological breakthroughs in molecular structure, polypeptide sequence and chemical modification, target, distribution and metabolism in human body. It is the only long-acting anti-HIV injection drug approved for listing in China market. Can be administered once a week, combined with other anti-AIDS drugs, can quickly and effectively inhibit the virus and improve immunity. In addition to inotropin and inotropin generic drug, Aikening is the only anti-HIV injection drug in China. It is a supplement and promotion to the current domestic treatment programs, mainly oral drug therapy, and has certain clinical irreplaceability, meeting some important clinical needs in the field of public health.
At the same time, Aikening also broke the monopoly of foreign pharmaceutical companies on new anti-AIDS drugs and established China's innovative ability in this field. Aikening's listing and broad market prospects provide a solid foundation for the company to further enhance its core competitiveness and new drug research and development strength.
At present, Frontier Biology and domestic clinical experts are actively carrying out post-marketing clinical research of Aikening, including clinical trials of Aikening for post-exposure prevention and its interaction with other drugs, in order to further explore the clinical value of Aikening.
The market demand is expanding! Frontier organisms raise funds to expand production and ensure the supply of "Aikening"
According to UNAIDS statistics, by the end of 20 18, the number of HIV carriers and AIDS patients in the world was about 37.9 million. According to the consulting report, it is estimated that by 2030, the global population infected with HIV will increase at a compound annual growth rate of 1.3%. Based on this huge population base, the market scale of anti-AIDS drugs will be further expanded.
In recent years, the development direction of global anti-HIV drugs mainly focuses on long-term, in-depth research and development of AIDS immunotherapy and AIDS prevention drugs, which are mainly used for maintenance treatment, but the functional cure of AIDS has not yet been realized. Frontier biological combination therapy faces the global market and is mainly sold in developed countries and China. Explore four indications of "multidrug resistance, maintenance treatment, immunotherapy and prevention", and plan to give drugs every 2 -4 weeks, which is expected to explore the functional cure of AIDS. If the combination therapy can be successfully developed to replace the global market of some mainstream oral drugs, it is expected that the global market space will be great.
In terms of industrialization, frontier biology has invested a lot of resources in the commercialization of Akening, and has GMP production facilities for clinical and commercial production of Akening, covering the national medical promotion team and overseas market development team. The company independently developed the production technology of Akening, including the core production technology and raw material formula. The company always regards GMP-certified production facilities as an important part of its core competitiveness, and constantly explores and improves the output and quality of its products. In addition, the company team has rich experience in drug research and development, drug manufacturing, market access, business operation, promotion and sales, which has laid a solid foundation for the company's continuous innovation, stable production and market development.
In terms of domestic market sales, since it was officially launched in August 20 18, Frontier Bio has signed commercial distribution and distribution agreements with large pharmaceutical distributors such as Sinopharm Holdings, Shanghai Pharmaceutical Holdings and Guangzhou Pharmaceutical, covering major regions such as East China, South China, Southwest China and Northeast China. By June 30, 2020, Aikening had been sold in 24 provinces, 52 cities, 70 designated AIDS treatment hospitals and 60 DTP pharmacies.
In terms of overseas market expansion, Akening's overseas sales will mainly focus on developing countries. Frontier Biology will work with qualified local or regional partners to carry out drug registration, distribution and professional academic promotion. As of June 30, 2020, the company has started the preparation for drug registration of Akening with overseas distributors in 24 countries (including South Africa, Thailand and other key countries), and has submitted drug registration applications in three of them: Malaysia, Myanmar and Ecuador.
Frontier Bio said that in the future, the company will actively expand the overseas sales of its products, and seek cooperation with multinational pharmaceutical companies with the help of Akening's global sales network to achieve the coverage and sales of combination therapy in the global market. Aikening's overseas sales will be mainly concentrated in developing countries, and the overseas sales of combination therapy will be mainly concentrated in developed countries, with broad market prospects.
At present, the production capacity of the frontier biological Gande Road production base is 6.5438+0.8 million tablets/year. The company plans to use part of the funds raised from this science and technology innovation board listing for the project of "654.38+00,000 pieces of HIV fusion inhibitor for injection" to enhance the production capacity of Aikening preparation. The design capacity of the first phase construction project of "1 000,000 HIV fusion inhibitor project for injection" is 2.5 million tablets/year. At the same time, in order to meet Akening's raw material demand, the company plans to build its own production bases in Qihe border and Sichuan border to ensure Akening's raw material supply. In terms of frontier biology, the implementation of the above-mentioned capacity expansion project will greatly alleviate the capacity limitation of Akening, meet the growing market demand and provide a solid foundation for the company's further development.
advertisement